Skip to main content

Table 1 Cytotoxicity of compounds 1, 2, 3, 4, 5, 6, 7 and 8 against hepatocellular carcinoma cell line HePG2

From: Design, synthesis and evaluation of anticancer activity of novel 2-thioxoimidazolidin-4-one derivatives bearing pyrazole, triazole and benzoxazole moieties

Concentration µg/mL

Viability (%)/compound

1

2

3

4

5

6

7

8

500

5.26

19.86

2.97

7.48

3.04

31.67

12.58

6.31

250

10.68

28.74

7.28

14.53

6.31

46.23

20.64

14.96

125

18.97

39.45

11.49

21.84

10.25

68.92

31.75

20.85

62.5

25.14

68.17

16.85

29.41

16.43

83.64

42.31

26.43

31.25

34.72

79.52

23.72

38.63

22. 37

93.51

64.15

38.14

15.6

48.25

91.43

30.85

49.56

30.69

99.48

79.27

47.59

7.8

62.89

98.76

41.93

71.38

38.15

100

88.74

60.31

3.9

78.03

100

51.58

85.97

46.36

100

96.13

73.86

2

86.26

100

62.72

92.04

59.02

100

99.47

85.23

1

90.41

100

70.88

97.13

74.15

100

100

90.67

0

100

100

100

100

100

100

100

100